Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Dec 04, 2020 7:30am EST

Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition

Nov 23, 2020 7:30am EST

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

Nov 17, 2020 7:30am EST

Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia

Nov 10, 2020 7:30am EST

Rigel to Present at the Jefferies Virtual London Healthcare Conference

Nov 05, 2020 4:01pm EST

Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update

Oct 29, 2020 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update

Oct 09, 2020 7:30am EDT

Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

Sep 17, 2020 7:30am EDT

Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

Sep 09, 2020 7:30am EDT

Rigel to Present at Two Upcoming Investor Conferences

Sep 02, 2020 7:30am EDT

Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference

  • Previous
  • 1…
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …42
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin